

# Chemical Safety Practices Recommendations

## Regorafenib (BAY73-4506, Stivarga)

Exposure Hazards(1, 2)			
<p>Category 2 Warning Toxic</p>  <p>Repeat or chronic exposure may damage skin, liver, and circulatory system.</p>	<p>Category 1B Danger</p>  <p>Toxic to Reproduction</p> <p>Exposure may harm fertility and unborn children. This drug may be passed through milk.</p>		
Response to Exposure			
Oral	Dermal	Inhalation	Injection
Rinse mouth; do not induce vomiting. Report to OHS.	Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS.	Leave area; go to clean air. Report to OHS.	Report to OHS.
<b>Special Precautions</b>	Pregnant women should be extra cautious when working with or around Regorafenib.		
<b>Personal Protective Equipment</b>	Gloves (double) (Latex or Nitrile) Skin Protection (Suit or Scrubs or Lab Coat) Eye Protection (Safety-glasses or Goggles) Closed-toe shoes Use N100 respirator if engineering controls are not available.		
<b>Engineering Controls</b>	Regorafenib powder- Chemical Fume Hood (CFH) (3) Regorafenib solution- CFH or Biosafety Cabinet (Class II, B2 BSC if aerosolized) Animal waste and bedding until 20 days after last treatment- CFH or Class II, B2 BSC 		
<b>Animal Handling</b>	Avoid exposure to animal waste/tissue until 20 days after last treatment. (4)		
<b>Bedding Disposal</b>	Dispose of bedding as hazardous material until 20 days after last treatment.		
<b>Work Practices</b>	Empty Regorafenib containers and unused Regorafenib must be disposed of as hazardous. Follow LASP SOPs for preparation, handling, dosing, and disposal of Regorafenib.		

# Chemical Safety Practices Recommendations

## Regorafenib (BAY73-4506, Stivarga)

### References:

1. Regorafenib Label [Internet]. USFDA. 2013 [cited 11/21/14]. Available from: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>.
2. Nations U. GLOBALLY HARMONIZED SYSTEM OF CLASSIFICATION AND LABELLING OF CHEMICALS (GHS) 5th ed2013.
3. National Research Council Committee on Prudent Practices in the L. The National Academies Collection: Reports funded by National Institutes of Health. Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: Updated Version. Washington (DC): National Academies Press (US) National Academy of Sciences.; 2011.
4. Strumberg D, Schultheis B. Regorafenib for cancer. Expert opinion on investigational drugs. 2012;21(6):879-89.